263 related articles for article (PubMed ID: 28445152)
81. Clinicopathological analysis of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma: are they just apples and oranges?
Chiu CT; Chiang JM; Yeh TS; Tseng JH; Chen TC; Jan YY; Chen MF
Dig Liver Dis; 2008 Sep; 40(9):749-54. PubMed ID: 18329969
[TBL] [Abstract][Full Text] [Related]
82. The DNA index as a prognostic tool in hilar cholangiocarcinoma.
Kamphues C; Al-Abadi N; Bova R; Rademacher S; Al-Abadi H; Klauschen F; Bahra M; Neuhaus P; Pratschke J; Seehofer D
J Surg Oncol; 2015 Aug; 112(2):214-8. PubMed ID: 26220797
[TBL] [Abstract][Full Text] [Related]
83. Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway.
Zhao S; Wang J; Qin C
J Exp Clin Cancer Res; 2014 Dec; 33(1):103. PubMed ID: 25471741
[TBL] [Abstract][Full Text] [Related]
84. Intrahepatic cholangiocarcinoma: current management and emerging therapies.
Rahnemai-Azar AA; Weisbrod AB; Dillhoff M; Schmidt C; Pawlik TM
Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):439-449. PubMed ID: 28317403
[TBL] [Abstract][Full Text] [Related]
85. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
Alvisi G; Termanini A; Soldani C; Portale F; Carriero R; Pilipow K; Costa G; Polidoro M; Franceschini B; Malenica I; Puccio S; Lise V; Galletti G; Zanon V; Colombo FS; De Simone G; Tufano M; Aghemo A; Di Tommaso L; Peano C; Cibella J; Iannacone M; Roychoudhuri R; Manzo T; Donadon M; Torzilli G; Kunderfranco P; Di Mitri D; Lugli E; Lleo A
J Hepatol; 2022 Nov; 77(5):1359-1372. PubMed ID: 35738508
[TBL] [Abstract][Full Text] [Related]
86. Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma.
Likhitrattanapisal S; Tipanee J; Janvilisri T
Tumour Biol; 2016 Sep; 37(9):12755-12766. PubMed ID: 27448818
[TBL] [Abstract][Full Text] [Related]
87. [Analysis of prognostic factors after curative resection for combined hepatocellular and cholangiocarcinoma].
Kim W; Lee JH; Kim YJ; Yoon JH; Suh KS; Lee KU; Jang JJ; Lee HS
Korean J Gastroenterol; 2007 Mar; 49(3):158-65. PubMed ID: 18172344
[TBL] [Abstract][Full Text] [Related]
88. Model to predict survival after surgical resection of intrahepatic cholangiocarcinoma: the Mayo Clinic experience.
Ali SM; Clark CJ; Mounajjed T; Wu TT; Harmsen WS; Reid-Lombardo KM; Truty MJ; Kendrick ML; Farnell MB; Nagorney DM; Que FG
HPB (Oxford); 2015 Mar; 17(3):244-50. PubMed ID: 25410716
[TBL] [Abstract][Full Text] [Related]
89. A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition.
Seok JY; Na DC; Woo HG; Roncalli M; Kwon SM; Yoo JE; Ahn EY; Kim GI; Choi JS; Kim YB; Park YN
Hepatology; 2012 Jun; 55(6):1776-86. PubMed ID: 22234953
[TBL] [Abstract][Full Text] [Related]
90. Decreased expression of TFPI-2 correlated with increased expression of CD133 in cholangiocarcinoma.
Chu X; Zhao P; Lv Y; Liu L
Int J Clin Exp Pathol; 2015; 8(1):328-36. PubMed ID: 25755719
[TBL] [Abstract][Full Text] [Related]
91. An Immunohistochemical Analysis of Osteopontin and S100 Calcium-binding Protein P is Useful for Subclassifying Large- and Small-duct Type Intrahepatic Cholangiocarcinomas.
Yoshizawa T; Uehara T; Iwaya M; Nakajima T; Shimizu A; Kubota K; Notake T; Kitagawa N; Masuo H; Sakai H; Hayashi H; Tomida H; Yamazaki S; Hirano S; Ota H; Soejima Y
Am J Surg Pathol; 2024 Jun; 48(6):751-760. PubMed ID: 38584480
[TBL] [Abstract][Full Text] [Related]
92. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.
Dong L; Lu D; Chen R; Lin Y; Zhu H; Zhang Z; Cai S; Cui P; Song G; Rao D; Yi X; Wu Y; Song N; Liu F; Zou Y; Zhang S; Zhang X; Wang X; Qiu S; Zhou J; Wang S; Zhang X; Shi Y; Figeys D; Ding L; Wang P; Zhang B; Rodriguez H; Gao Q; Gao D; Zhou H; Fan J
Cancer Cell; 2022 Jan; 40(1):70-87.e15. PubMed ID: 34971568
[TBL] [Abstract][Full Text] [Related]
93. Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification.
Walter D; Ferstl P; Waidmann O; Trojan J; Hartmann S; Schnitzbauer AA; Zeuzem S; Kraywinkel K
Liver Int; 2019 Feb; 39(2):316-323. PubMed ID: 30176117
[TBL] [Abstract][Full Text] [Related]
94. Glycosylation of FGFR4 in cholangiocarcinoma regulates receptor processing and cancer signaling.
Phillips AJ; Lobl MB; Hafeji YA; Safranek HR; Mohr AM; Mott JL
J Cell Biochem; 2022 Mar; 123(3):568-580. PubMed ID: 34981854
[TBL] [Abstract][Full Text] [Related]
95. EGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinoma.
Hoffmann AC; Goekkurt E; Danenberg PV; Lehmann S; Ehninger G; Aust DE; Stoehlmacher-Williams J
PLoS One; 2013; 8(5):e64186. PubMed ID: 23704979
[TBL] [Abstract][Full Text] [Related]
96. Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis.
Alvarez-Sola G; Uriarte I; Latasa MU; Urtasun R; Bárcena-Varela M; Elizalde M; Jiménez M; Rodriguez-Ortigosa CM; Corrales FJ; Fernández-Barrena MG; Berasain C; Avila MA
Dig Dis; 2017; 35(3):158-165. PubMed ID: 28249259
[TBL] [Abstract][Full Text] [Related]
97. Endogenous CXCL9 affects prognosis by regulating tumor-infiltrating natural killer cells in intrahepatic cholangiocarcinoma.
Fukuda Y; Asaoka T; Eguchi H; Yokota Y; Kubo M; Kinoshita M; Urakawa S; Iwagami Y; Tomimaru Y; Akita H; Noda T; Gotoh K; Kobayashi S; Hirata M; Wada H; Mori M; Doki Y
Cancer Sci; 2020 Feb; 111(2):323-333. PubMed ID: 31799781
[TBL] [Abstract][Full Text] [Related]
98. Filamin A is involved in human intrahepatic cholangiocarcinoma aggressiveness and progression.
Vitali E; Franceschini B; Milana F; Soldani C; Polidoro MA; Carriero R; Kunderfranco P; Trivellin G; Costa G; Milardi G; Di Tommaso L; Torzilli G; Lleo A; Lania AG; Donadon M
Liver Int; 2024 Feb; 44(2):518-531. PubMed ID: 38010911
[TBL] [Abstract][Full Text] [Related]
99. Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis.
Wiggers JK; Ruys AT; Groot Koerkamp B; Beuers U; ten Kate FJ; van Gulik TM
J Gastroenterol Hepatol; 2014 Aug; 29(8):1582-94. PubMed ID: 24787096
[TBL] [Abstract][Full Text] [Related]
100. Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas.
Jomrich G; Hudec X; Harpain F; Winkler D; Timelthaler G; Mohr T; Marian B; Schoppmann SF
Cells; 2019 Sep; 8(9):. PubMed ID: 31527546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
